New combo therapy shows promise for aggressive breast cancer in early trial

NCT ID NCT06817525

Recruiting now Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (Camrelizumab) given before surgery can eliminate all cancer in patients with early triple-negative breast cancer. About 64 participants will receive this treatment to see how many achieve a complete response (no cancer left at surgery). The goal is to find a more effective approach for this aggressive cancer type.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Henan cancer hospital
RECRUITING

Zhengzhou, Henan, China

Contact Phone: •••-•••-•••• Email: •••••@•••••